非霍奇金淋巴瘤相关噬血细胞综合征的临床特征与治疗结局
该回顾性研究纳入89例非霍奇金淋巴瘤相关噬血细胞综合征患者,中位总生存10.2个月,B细胞型未达中位生存,T细胞型10.2个月,NK细胞型3.0个月。病理类型、ECOG评分≥3、造血干细胞移植、淋巴结肿大与生存相关,脾切除可改善预后。
要点
- 不同病理类型非霍奇金淋巴瘤相关HLH的长期生存率不同。
- B细胞和NK细胞型应尽早行造血干细胞移植以改善预后。
- T细胞型可考虑脾切除手术改善生存。
核心结论
- 不同病理类型非霍奇金淋巴瘤相关HLH临床特点相似但长期生存率和预后影响因素不同。
- 非霍奇金淋巴瘤相关HLH不仅需要联合化疗,B细胞和NK细胞型需尽早移植,T细胞型应考虑脾切除。
研究设计与样本
- 回顾性分析2013年3月至2020年5月复旦大学附属华东医院89例非霍奇金淋巴瘤相关HLH患者临床资料。
- 采用Log-rank法单因素分析和Cox比例风险回归模型多因素分析预后因素。
主要发现
- 89例患者中位总生存时间10.2个月。
- B细胞淋巴瘤相关HLH未达到中位总生存时间,T细胞型中位总生存10.2个月,NK细胞型3.0个月,差异有统计学意义(P=0.012)。
- 病理类型与OS(P=0.041)和PFS(P=0.015)相关。
- ECOG评分≥3与OS(P=0.031)和PFS(P=0.030)相关,造血干细胞移植与OS(P=0.005)和PFS(P=0.040)相关。
- 淋巴结肿大与OS(P=0.007)和PFS(P=0.012)相关,脾脏肿大与OS(P=0.276)和PFS(P=0.324)相关。
关键数值与推荐
- 不同病理类型中位总生存:B细胞型未达到,T细胞型10.2个月,NK细胞型3.0个月(P=0.012)。
- 病理类型:OS P=0.041,PFS P=0.015;ECOG≥3:OS P=0.031,PFS P=0.030。
- 造血干细胞移植:OS P=0.005,PFS P=0.040;淋巴结肿大:OS P=0.007,PFS P=0.012。
- 脾脏肿大:OS P=0.276,PFS P=0.324。
临床怎么用
- 对非霍奇金淋巴瘤相关HLH应联合化疗外积极考虑移植或脾切除等个体化治疗。
- B细胞和NK细胞淋巴瘤相关HLH患者应尽早评估并接受造血干细胞移植。
- T细胞淋巴瘤相关HLH患者可考虑脾切除手术以改善预后。
局限性
- 本研究为单中心回顾性分析,样本量89例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To investigate the clinical features and effect of prognostic factors in patients with different pathological types of non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis. Methods: We collected and analyzed the clinical data of 89 patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis who were treated at Huadong Hospital from March 2013 to May 2020. The data were analyzed via log-rank and Cox multivariate analyses. Results: The median overall survival time of the 89 cases was 10.2 months. Patients with B-cell lymphoma-associated hemophagocytic lymphohistiocytosis did not reach the median overall survival time. The median overall survival times of T-cell lymphoma-associated hemophagocytic lymphohistiocytosis and NK-cell lymphoma-associated hemophagocytic lymphohistiocytosis were 10.2 and 3.0 months, respectively. The pathological type of non-Hodgkin lymphoma (OS: P=0041, PFS: P=0.015) , ECOG score ≥ 3 (OS: P=0.031, PFS: P=0.030) , hematopoietic stem cell transplantation (OS: P=0.005, PFS: P=0.040) , lymphadenopathy (OS: P=0.007, PFS: P=0.012) , and splenomegaly (OS: P=0.276, PFS: P=0.324) were related to the overall survival and progression-free survival of patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis. Splenectomy could improve the prognosis of patients with lymphoma-associated hemophagocytic lymphohistiocytosis, especially T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. Conclusion: The clinical characteristics of patients with different pathological types of non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis were similar but were different in the overall survival rate and the effect of prognostic factors. We suggested that patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis should receive more than combined chemotherapy. To improve the prognosis and survival rate of patients, those with B-cell lymphoma-associated hemophagocytic lymphohistiocytosis and NK-cell lymphoma-associated hemophagocytic lymphohistiocytosis promptly require hematopoietic stem cell transplantation. Moreover, patients with T-cell lymphoma-associated hemophagocytic lymphohistiocytosis should consider splenectomy. 目的: 回顾性分析不同病理类型非霍奇金淋巴瘤相关噬血细胞综合征(HLH)的临床特征及预后影响因素。 方法: 收集和分析2013年3月至2020年5月复旦大学附属华东医院确诊的89例非霍奇金淋巴瘤相关HLH患者的临床资料,应用Log-rank法对影响预后的因素进行单因素分析,应用Cox比例风险回归模型进行多因素分析。 结果: 89例淋巴瘤相关HLH患者中位生存时间10.2个月,B细胞淋巴瘤患者未达到中位生存时间,T细胞淋巴瘤患者中位生存时间10.2个月,NK细胞淋巴瘤患者中位生存时间为3个月,差异具有统计学意义(P=0.012)。非霍奇金淋巴瘤病理类型[总生存(OS):P=0.041,无进展生存(PFS):P=0.015],美国东部肿瘤协作组评分(OS:P=0.031,PFS:P=0.030),是否行造血干细胞移植(OS:P=0.005,PFS:P=0.040),是否伴淋巴结肿大(OS:P=0.007,PFS:P=0.012),是否伴脾脏肿大(OS:P=0.276,PFS:P=0.324)是影响非霍奇金淋巴瘤相关HLH患者OS和PFS的因素。脾脏切除手术能够改善淋巴瘤相关HLH患者的生存,尤其是T细胞淋巴瘤相关HLH。 结论: 不同病理类型非霍奇金淋巴瘤相关HLH患者临床特点相似,但长期生存率和预后影响因素不同。非霍奇金淋巴瘤相关HLH不仅需要联合化疗,B细胞淋巴瘤和NK细胞淋巴瘤相关HLH患者需尽早进行造血干细胞移植,T细胞淋巴瘤相关HLH患者应考虑脾脏切除手术,以改善患者预后。.
引用
- Sun SR, Wu M, Wulipan F, et al. [Clinical features and treatment outcome of patients with non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 33979978. doi:10.3760/cma.j.issn.0253-2727.2021.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。